FDA Accepts Bristol-Myers' Mavacamten Application In Inherited Heart Disease For Review

The FDA has accepted for review Bristol-Myers Squibb Co's BMY marketing application for mavacamten for symptomatic obstructive hypertrophic cardiomyopathy.

• The FDA has assigned a goal date of January 28, 2022.
• Hypertrophic cardiomyopathy is a disease in which the heart muscle becomes abnormally thick, making it harder for the heart to pump blood.
• Mavacamten is an allosteric modulator of cardiac myosin that reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation.
• Price Action: BMY shares are up 0.5% at $62.63 in premarket trading on the last check Friday.